TIDMABC
RNS Number : 7499R
ABCAM PLC
18 June 2018
18 June 2018
ABCAM PLC
Appointment of Chairman
Abcam plc ("Abcam" or "the Company", AIM: ABC), a global leader
in the supply of life science research tools, is pleased to
announce the appointment of Peter Allen as non-executive Chairman
with immediate effect.
Peter assumes the role of Chairman from Louise Patten, who has
been serving as interim Chairman and will revert to a non-executive
Director.
Peter has over 20 years' experience as an executive director,
non-executive director and Chairman in a wide range of life science
companies. He is currently non-executive Chairman of AIM-listed
companies Clinigen plc, Advanced Medical Solutions plc and Diurnal
Group plc, as well as privately owned Oxford Nanopore Technologies
Limited, and is also a non-executive director of privately owned
Istesso Limited. From 1992-2004 Peter served as Chief Financial
Officer of Celltech Group plc.
Louise Patten, Interim Chairman of Abcam and Interim Chairman of
the Nomination Committee, said: "Following a thorough process, the
Board was unanimous in their view that Peter is the right candidate
to chair Abcam. We are confident that his wide business experience,
his industry knowledge and his personal qualities will enable him
to make a significant contribution to the future of the
Company."
Peter Allen commented: "I am looking forward to taking on the
role of Chairman and am delighted to have the opportunity to help
take Abcam to the next stage in its development and growth. I look
forward to working with Alan Hirzel, his executive team and the
Board in implementing the Company's strategic vision and building
on its position as global leader in the sale of research reagents
to deliver continued long term, profitable growth."
Following the appointment of Peter Allen, Louise Patten has
resumed her position as Senior Independent Director, which had been
performed by Mara Aspinall on an interim basis during the search
process.
The process to appoint Peter Allen was led by Louise Patten,
Interim Chairman. The Nomination Committee appointed the leading
executive search and board advisory consulting firm Lygon Group to
conduct the search for a new Chairman. An extensive search was
conducted and a shortlist of candidates was agreed before
interviews were conducted.
The Board considers Peter to be independent, as defined by Code
Provision B.1.2 of the UK Corporate Governance Code. Peter does not
currently have any interests in Abcam shares.
The composition of each of the Board Committees has also been
amended and is confirmed as follows:
Board Committee Membership
Nomination Committee Peter Allen (Chairman)
Louise Patten
Sue Harris
Mara Aspinall
=========================
Remuneration Committee Louise Patten (Chairman)
Peter Allen
Sue Harris
Mara Aspinall
=========================
Audit and Risk Committee Sue Harris (Chairman)
Peter Allen
Louise Patten
=========================
AIM Rules disclosures
Peter Vance Allen (age 62) holds or has held directorships in
the five years preceding his appointment at Abcam as follows:
Current directorships Previous Directorships
Diurnal Group plc Future plc
=============================
Advanced Medical Solutions plc ProStrakan Group plc
=============================
Clinigen plc Chroma Therapeutics Ltd
=============================
Oxford Nanopore Technologies Proximagen Neurosciences plc
Ltd
=============================
Istesso Ltd Mecom plc
=============================
Scancell plc
=============================
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Suzanne Smith, Chief Legal Officer and Company Secretary
James Staveley, VP, Investor Relations
J.P. Morgan Cazenove - Nominated Advisor & Corporate
Broker
+ 44 (0) 20 7742 4000
James Mitford
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the c.56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's eleven locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKMGMVFRFGRZM
(END) Dow Jones Newswires
June 18, 2018 09:54 ET (13:54 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024